Journal of Reproductive Immunology
Volume 82, Issue 2 , Pages 106-111 , November 2009

Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia—a step forward but not the definitive answer

  • J.M. Foidart

      Affiliations

    • University of Liege, Department of Obstetrics and Gynaecology, Hospital de la Citadelle, Blvd du XIIeme de Ligne, 4000 Liege, Belgium
    • Laboratory of Biology and Tumor Development, Hospital de la Citadelle, Blvd du XIIeme de Ligne, 4000 Liege, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 495 541 887; fax: +32 42240005.
    • ,
  • J.P. Schaaps

      Affiliations

    • University of Liege, Department of Obstetrics and Gynaecology, Hospital de la Citadelle, Blvd du XIIeme de Ligne, 4000 Liege, Belgium
    • ,
  • F. Chantraine

      Affiliations

    • University of Liege, Department of Obstetrics and Gynaecology, Hospital de la Citadelle, Blvd du XIIeme de Ligne, 4000 Liege, Belgium
    • ,
  • C. Munaut

      Affiliations

    • Laboratory of Biology and Tumor Development, Hospital de la Citadelle, Blvd du XIIeme de Ligne, 4000 Liege, Belgium
    • ,
  • S. Lorquet

      Affiliations

    • University of Liege, Department of Obstetrics and Gynaecology, Hospital de la Citadelle, Blvd du XIIeme de Ligne, 4000 Liege, Belgium
    • Laboratory of Biology and Tumor Development, Hospital de la Citadelle, Blvd du XIIeme de Ligne, 4000 Liege, Belgium

Received 24 December 2008 ,Revised 23 September 2009 ,Accepted 23 September 2009.

References 

  1. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in PE mediate enhanced angiotensin II responsiveness. Nat. Med. 2001;7:1003–1009
  2. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in PE. Circ. Res. 2004;95:884–891
  3. Ballermann BJ. Glomerular endothelial cell differentiation. Kidney Int. 2005;67:1668–1671
  4. Baumwell S, Karumanchi SA. PE: clinical manifestations and molecular mechanisms. Nephron. Clin. Pract. 2007;106(2):c72–c81
  5. Blouin CC, Pagé EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood. 2004;103:1124–1130
  6. Davidge ST. Oxidative stress and altered endothelial cell function in PE. Semin. Reprod. Endocrinol. 1998;16:65–73
  7. De Wolf F, De Wolf-Peeters C, Brosens I, Robertson WB. The human placental bed: electron microscopic study of trophoblastic invasion of spiral arteries. Am. J. Obstet. Gynecol. 1980;137:58–70
  8. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 2003;111:707–716
  9. Foidart JM, Hustin J, Dubois M, Schaaps JP. The human placenta becomes haemochorial at the 13th week of pregnancy. Int. J. Dev. Biol. 1992;36:451–453
  10. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Allen Hogge W, Conrad KP. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta. 2008;November 20 (Epub ahead of print)
  11. Görlach A, Bonello S. The cross-talk between NF-kB and HIF-1: further evidence for a significant liaison. Biochem. J. 2008;412:e17–e19
  12. Hubel CA, McLaughlin MK, Evans RW, Hauth BA, Sims CJ, Roberts JM. Fasting serum triglycerides, free fatty acids, and malondialdehyde are increased in PE, are positively correlated, and decrease within 48 hours post partum. Am. J. Obstet. Gynecol. 1996;174:975–982
  13. Hung TH, Burton GJ. Hypoxia and reoxygenation: a possible mechanism for placental oxidative stress in PE. Taiwan J. Obstet. Gynecol. 2006;45:189–200
  14. Hustin J, Schaaps JP. Echo(cardio)graphic and anatomic studies of the materno trophoblastic border during the first trimester of pregnancy. Am. J. Obstet. Gynecol. 1987;157(1):162–168
  15. Kolben M, Lopens A, Blaser J, Huber A, Frank M, Wilhelm O, et al Measuring the concentration of various plasma and placenta extract proteolytic and vascular factors in pregnant patients with HELLP syndrome, pre-/eclampsia and highly pathologic Doppler flow values. Gynaekol. Geburtsh. Rundsch. 1995;35(Suppl. 1):126–131
  16. Kontic-Vucinic O, Terzic M, Radunovic N. The role of antioxidant vitamins in hypertensive disorders of pregnancy. J. Perinat. Med. 2008;36(4):282–290
  17. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol. 2002;22:1500–1505
  18. Karumanchi SA, Lindheimer MD. Advances in the understanding of eclampsia. Curr. Hypertens. Rep. 2008;10(August (4)):305–312
  19. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in PE. N. Engl. J. Med. 2006;355:992–1005
  20. Li X, Shams M, Zhu J, Khalig A, Wilkes M, Whittle M, et al. Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants. J. Clin. Invest. 1998;101:442–454
  21. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, et al. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum. Reprod. 2008;23(June (6)):1407–1415
  22. Maynard S, Epstein FH, Karumanchi SA. PE and angiogenic imbalance. Annu. Rev. Med. 2008;59:61–78
  23. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in PE. J. Clin. Invest. 2003;111:649–658
  24. Myatt L, Rosenfield RB, Eis AL, Brockman DE, Greer I, Lyall F. Nitrotyrosine residues in placenta. Evidence of peroxynitrite formation and action. Hypertension. 1996;28:488–493
  25. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006;291:R1085–R1093
  26. Pregnancy: Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am. J. Obstet. Gynecol. 2000;183:S1–S22
  27. Qin Z. Newly developed angiotensin II-infused experimental models in vascular biology. Regul. Pept. 2008;150:1–6
  28. Redman C, Sargent IL. Placental stress and PE: a revised view placenta 30, supplement A. Trophoblast Res. 2009;23:S38–S42
  29. Redman CW, Sargent IL. Latest advances in understanding PE. Science. 2005;308:1592–1594
  30. Redman CWG, Sargent IL. Circulating microparticles in normal pregnancy and PE placenta 29, supplement A. Trophoblast Res. 2008;22:S73–S77
  31. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-kB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453:807–811
  32. Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J. Pathol. Bacteriol. 1967;93:581–592
  33. Rumbold A, Duley L, Crowther CA, Haslam RR. Antioxidants for preventing PE. Cochrane Database Syst. Rev. 2008;(January (1)):CD004227
  34. Schaaps JP, Foidart JM. Uteroplacental circulation. Rev. Fr. Gynecol. Obstet. 1991;86:579–584
  35. Schaaps JP, Tsatsaris V, Goffin F, Brichant JF, Delbecque K, Tebache M, et al. Shunting the intervillous space: new concepts in human uteroplacental vascularization. Am. J. Obstet. Gynecol. 2005;192(January (1)):323–332
  36. Shah DM. Preeclampsia, new insights. Curr. Opin. Nephrol. Hypertens. 2007;16:213–220
  37. Stella CL, Sibai BM. Preeclampsia: diagnosis and management of the atypical presentation. J. Matern. Fetal Neonatal Med. 2006;19:381–386
  38. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kB in hypoxic inflammation. J. Physiol. 2008;586:4055–4059
  39. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kB. Biochem. J. 2008;412:477–484
  40. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of PE. Nat. Med. 2006;12:642–649
  41. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, et al. Patients with PE develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 1999;103:945–952
  42. Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of PE. Hypertension. 2007;50(August (2)):269–275
  43. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003;349:427–434
  44. Zhou Y, Damsky CH, Fisher SJ. PE is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J. Clin. Invest. 1997;99:2152–2164

PII: S0165-0378(09)00451-3

doi: 10.1016/j.jri.2009.09.001

Journal of Reproductive Immunology
Volume 82, Issue 2 , Pages 106-111 , November 2009

Article Tools